tiprankstipranks
Advertisement
Advertisement

BMY Stock Latest News

Real-World Data on Nivolumab Plus Chemo in Japanese Gastric Cancer: What Investors Should Watch
Company AnnouncementsReal-World Data on Nivolumab Plus Chemo in Japanese Gastric Cancer: What Investors Should Watch
4d ago
BMY
Bristol-Myers Squibb’s Real World Kidney Cancer Study Signals Durable Immunotherapy Momentum
PremiumCompany Announcements
Bristol-Myers Squibb’s Real World Kidney Cancer Study Signals Durable Immunotherapy Momentum
6d ago
BMY
J&J, Bristol-Myers face negotiation risk under new CMS rule, says RBC Capital
PremiumThe Fly
J&J, Bristol-Myers face negotiation risk under new CMS rule, says RBC Capital
7d ago
BMY
JNJ
CMS proposes to lock in lower prices in Medicare drug price negotiation program
PremiumThe Fly
CMS proposes to lock in lower prices in Medicare drug price negotiation program
7d ago
AZN
BMY
Bristol-Myers Squibb Advances Phase 1 Liver Study for New Drug BMS-986435
PremiumCompany Announcements
Bristol-Myers Squibb Advances Phase 1 Liver Study for New Drug BMS-986435
10d ago
BMY
Bristol-Myers Squibb’s Mavacamten Study Signals Real‑World Momentum in Heart Drug Market
PremiumCompany AnnouncementsBristol-Myers Squibb’s Mavacamten Study Signals Real‑World Momentum in Heart Drug Market
10d ago
BMY
Heart-Disease Biotech Kardigan Set For $1.4B U.S. IPO
Premium
Market News
Heart-Disease Biotech Kardigan Set For $1.4B U.S. IPO
11d ago
BMY
JEF
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
18d ago
AZN
BMY
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
PremiumRatings
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
18d ago
BMY
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
PremiumThe Fly
Arcus enters clinical trial collaboration, supply agreement with Bristol Myers
19d ago
BMY
RCUS
Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors
PremiumCompany Announcements
Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors
20d ago
BMY
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
20d ago
AZN
BMY
Bristol Myers, SystImmune announce results from analyses of iza-bren studies
PremiumThe FlyBristol Myers, SystImmune announce results from analyses of iza-bren studies
20d ago
BMY
Bristol Myers: Opdivo in combination with AVD receives expanded EU label
Premium
The Fly
Bristol Myers: Opdivo in combination with AVD receives expanded EU label
21d ago
BMY
Bristol Myers says FDA accepts sNDA for Camzyos
Premium
The Fly
Bristol Myers says FDA accepts sNDA for Camzyos
21d ago
BMY
BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial
PremiumThe Fly
BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial
21d ago
BMY
BNTX
Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside
PremiumCompany Announcements
Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside
24d ago
BMY
Bristol-Myers Squibb Backs New Cell Therapy Combo in Early GI Cancer Trial
PremiumCompany Announcements
Bristol-Myers Squibb Backs New Cell Therapy Combo in Early GI Cancer Trial
24d ago
BMY
C4 Therapeutics jumps after Bristol Myers myeloma data
PremiumThe Fly
C4 Therapeutics jumps after Bristol Myers myeloma data
24d ago
BMY
CCCC
Why Penny Stock Replimune (REPL) Nearly Doubled Today
PremiumMarket NewsWhy Penny Stock Replimune (REPL) Nearly Doubled Today
24d ago
BMY
REPL
Bristol Myers says CELMoD mezigdomide reduces risk of disease progression by 52%
Premium
The Fly
Bristol Myers says CELMoD mezigdomide reduces risk of disease progression by 52%
24d ago
BMY
Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential
Premium
Ratings
Bristol-Myers Squibb: Hold Rating Reiterated as Analyst Maintains $61 Price Target Amid Near-Term Uncertainties and Long-Term Pipeline Potential
24d ago
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >